ClinicalTrials.gg
CompletedNCT04426825Updated May 21, 2024Results posted

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of Atezolizumab and Bevacizumab in Carcinoma, Non-Small-Cell Lung, sponsored by Hoffmann-La Roche. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 27 under way, 5 of them phase 3. atezolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
67th of 81
23 · median 80
Started
2020
with 8 others
Phase 2
48 of 81
8 open now
Registered
53rd of 81
by date
Lead sponsor
22 of 81
Hoffmann-La Roche

Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 67th largest by enrollment, is one of 9 that started in 2020, is one of 48 in phase 2, and was the 53rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 6 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 10 months
  • or cytologically confirmed stage IIIB, IIIC, or IV non-squamous NSCLC. Patients with tumors of mixed histology are eligible if the major histological component appears to be non-squamous.
  • No prior treatment for Stage IIIB, IIIC, or IV non-squamous NSCLC, with the following exceptions:

Patients with a sensitizing mutation in the EGFR gene must have experienced disease progression or were intolerant to treatment with one or more EGFR TKIs. Patients who have progressed on or were intolerant to osimertinib or other thirdgeneration EGFR TKIs are eligible.

Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs, and who have no evidence of the EGFR T790M mutation after TKI therapy are eligible.

Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs and who have evidence of the T790M mutation must have also progressed on or were intolerant to osimertinib to be eligible.

  • TKIs approved for treatment of NSCLC discontinued >7 days prior to enrollment.
  • per v1.1. expression of ≥1% as documented through central testing of a representative tumor tissue specimen either from previously obtained or tissue obtained from a biopsy at screening
  • Performance Status of 0-1
  • Adequate hematologic and end-organ function
  • Negative test at screening
  • Negative surface antigen (HBsAg) test at screening
  • Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive total HBcAb test.
  • Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods, and agreement to refrain from donating eggs.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic, untreated, or actively progressing central nervous system (CNS) as determined by CT or MRI evaluation during screening and prior radiographic assessments
  • History of
  • Prior chemotherapy or other systemic therapy for stage IIIB, IIIC, or IV disease
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Active tuberculosis
  • Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  • History of other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  • Current treatment with anti-viral therapy for
  • Treatment with therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
  • Treatment with systemic medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulations
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab, 6 months after the final dose of bevacizumab
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease within 6 months prior to initiation of study treatment
  • History of Grade ≥ 2 hemoptysis within 1 month prior to enrollment
  • Evidence of bleeding diathesis or coagulopathy. Current or recent use of aspirin, clopidogrel or treatment with dipyramidole, ticlopidine, or cilostazol
  • Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for > 2 weeks prior to enrollment
  • History of stroke or within 6 months prior to enrollment
  • Core or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab
  • History of abdominal or tracheosphageal fistula or gastrointestinal perforation within 6 months prior to enrollment
  • History of intra-abdominal inflammatory process within 6 months prior to initiation of study treatment, including but not limited to active peptic ulcer disease, diverticulitis,or colitis
  • Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
  • Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
  • Proteinuria
  • Clear tumor infiltration into the thoracic great vessels is seen on imaging
  • Clear cavitation of pulmonary lesions is seen on imaging
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Atezolizumab plus Bevacizumab

    Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death.

    Drug: Atezolizumab · Drug: Bevacizumab

Interventions

  • Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.

    Also known as: Tecentriq

  • Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate (ORR) was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).

    Time frame: Baseline up to approximately 10 months

Secondary outcomes

  1. Duration of Objective Response (DOR)

    Duration of objective response (DOR) was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to RECIST v1.1.

    Time frame: Baseline up to approximately 2.5 years

  2. Time to Response (TTR)

    Time to response (TTR) was defined as the time from the start of the treatment to the first objective tumor response observed for participants who achieved CR or PR, as determined by the investigator according to RECIST v1.1.

    Time frame: Baseline up to approximately 2.5 years

  3. Disease Control Rate (DCR)

    Disease control rate (DCR) was defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to RECIST v1.1.

    Time frame: Baseline up to approximately 2.5 years

  4. Overall Survival (OS)

    OS after enrollment was defined as the time from enrollment to death from any cause.

    Time frame: Baseline until death due to any cause (up to approximately 2.5 years)

  5. Progression-Free Survival (PFS)

    Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.

    Time frame: Baseline up to approximately 2.5 years

  6. PFS Rate at 6 and 12 Months

    PFS rate at 6 and 12 months is defined as the percentage of participants who have not experienced disease progression or death from any cause at 6 and 12 months, as determined by the investigator according to RECIST v1.1.

    Time frame: Baseline to 6 months and 12 months

  7. OS Rate at 1 and 2 Years

    OS rate at 1 and 2 years was defined as the percentage of participants who have not experienced death from any cause at 1 and 2 years.

    Time frame: Baseline to 1 and 2 Years

  8. Percentage of Participants With Adverse Events

    Percentage of participants with adverse events.

    Time frame: Baseline up to approximately 2.5 years

  9. Percentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs)

    Percentage of serious and non-serious immune-mediated adverse events related to atezolizumab treatment. The AESIs were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. The grading is as follows: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE.

    Time frame: Baseline up to approximately 2.5 years

  10. Objective Response Rate (ORR) According to iRECIST

    Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to Modified RECIST v1.1 (iRECIST).

    Time frame: Baseline up to approximately 2.5 years

  11. Disease Control Rate (DCR) According to iRECIST

    Disease control rate (DCR) is defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to modified RECIST v1.1 (iRECIST).

    Time frame: Baseline up to 2 years and approximately 5 months

  12. Duration of Objective Response (DOR) According to iRECIST

    Duration of objective response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).

    Time frame: Baseline up to approximately 2.5 years

  13. Progression-Free Survival (PFS) According to iRECIST

    Progression-free survival (PFS) is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).

    Time frame: Baseline up to approximately 2.5 years

  14. Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST

    Progression-free survival (PFS) rate is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first at 12 months, as determined by the investigator according to modified RECIST v1.1 (iRECIST).

    Time frame: Baseline up to approximately 12 months

  15. Time to Deterioation (TTD) Using EORTC

    Time to deterioration (TTD) using European Organization for Research and treatment of Cancer (EORTC) Quality-of-life Questionnaire Core 30 (QLQ C30) and its Lung Cancer Module (QLQ LC13) is defined as the time from baseline to the first time the patient's score shows a \>=10 points increase above baseline in any of the following EORTC-transformed symptom subscale scores (whichever occurs first): cough, dyspnoea (single item), dyspnoea (multi-item subscale), chest pain, or arm/shoulder pain, whichever occurred first. Scores ranged from 0-10. A higher score represented more severe symptoms.

    Time frame: Baselsine up to approximately 1 year

  16. Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status

    The 30-item EORTC QLQ-C30 version 3 is composed by five multi-item function scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), six single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), and a two-item global quality of life scale. All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for the functional and general health areas represent better functional status and quality of life. Higher scores for the symptom scales represent more symptoms or problems (poor quality of life). A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.

    Time frame: Baseline up to approximately 1 year

  17. Change From Baseline in Lung Cancer Related Symptoms

    The EORTC QLQ-LC13 is a specific module for lung cancer. It consists of 13 items covering lung cancer symptoms (dyspnoea, coughing, hemoptysis, pain in chest, pain in arm or shoulder and pain in other parts) and the side effects of chemo- and radiotherapy (alopecia, peripheral neuropathy, sore mouth, and dysphagia), which are divided into 10 fields, all are symptom types. All EORTC symptom scores are linearly transformed so that each score has a range of 0-100. A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.

    Time frame: Baseline up to approximately 1 year

07

Results

Posted Apr 13, 2023

Participant flow

This study was conducted at multiple investigational sites in China

Participant flow — Overall Study
MilestoneAtezolizumab Plus Bevacizumab
Started23
Completed0
Not completed23
Withdrew: Death17
Withdrew: Lost to follow-up1
Withdrew: Study terminated by sponsor5

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective response rate (ORR) was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).

Time frame:
Baseline up to approximately 10 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsAtezolizumab Plus Bevacizumab
Objective Response Rate (ORR)18.2 (5.19 to 40.28)
SecondaryDuration of Objective Response (DOR)

Duration of objective response (DOR) was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to RECIST v1.1.

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Median · Months
Duration of Objective Response (DOR)
MonthsAtezolizumab Plus Bevacizumab
Duration of Objective Response (DOR)6.36 (2.66 to NA)
SecondaryTime to Response (TTR)

Time to response (TTR) was defined as the time from the start of the treatment to the first objective tumor response observed for participants who achieved CR or PR, as determined by the investigator according to RECIST v1.1.

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Mean · Months
Time to Response (TTR)
MonthsAtezolizumab Plus Bevacizumab
Time to Response (TTR)1.577 ± 0.490
SecondaryDisease Control Rate (DCR)

Disease control rate (DCR) was defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to RECIST v1.1.

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsAtezolizumab Plus Bevacizumab
Disease Control Rate (DCR)65.2 (42.73 to 83.62)
SecondaryOverall Survival (OS)

OS after enrollment was defined as the time from enrollment to death from any cause.

Time frame:
Baseline until death due to any cause (up to approximately 2.5 years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAtezolizumab Plus Bevacizumab
Overall Survival (OS)14.06 (8.80 to 22.14)
SecondaryProgression-Free Survival (PFS)

Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsAtezolizumab Plus Bevacizumab
Progression-Free Survival (PFS)2.76 (1.35 to 4.07)
SecondaryPFS Rate at 6 and 12 Months

PFS rate at 6 and 12 months is defined as the percentage of participants who have not experienced disease progression or death from any cause at 6 and 12 months, as determined by the investigator according to RECIST v1.1.

Time frame:
Baseline to 6 months and 12 months
Reported as:
Number · Percentage of participants
PFS Rate at 6 and 12 Months
Percentage of participantsAtezolizumab Plus Bevacizumab
6 months13.91 (3.49 to 31.36)
12 months4.64 (0.33 to 19.26)
SecondaryOS Rate at 1 and 2 Years

OS rate at 1 and 2 years was defined as the percentage of participants who have not experienced death from any cause at 1 and 2 years.

Time frame:
Baseline to 1 and 2 Years
Reported as:
Number · Percentage of participants
OS Rate at 1 and 2 Years
Percentage of participantsAtezolizumab Plus Bevacizumab
1 year52.17 (30.51 to 70.01)
2 years30.43 (13.54 to 49.28)
SecondaryPercentage of Participants With Adverse Events

Percentage of participants with adverse events.

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events
ParticipantsAtezolizumab Plus Bevacizumab
Percentage of Participants With Adverse Events23
SecondaryPercentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs)

Percentage of serious and non-serious immune-mediated adverse events related to atezolizumab treatment. The AESIs were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. The grading is as follows: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE.

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Count of participants · Participants
Percentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs)
ParticipantsAtezolizumab Plus Bevacizumab
Non-serious irAEs7
Serious irAEs1
SecondaryObjective Response Rate (ORR) According to iRECIST

Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to Modified RECIST v1.1 (iRECIST).

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) According to iRECIST
Percentage of ParticipantsAtezolizumab Plus Bevacizumab
Objective Response Rate (ORR) According to iRECIST17.4 (4.95 to 38.78)
SecondaryDisease Control Rate (DCR) According to iRECIST

Disease control rate (DCR) is defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to modified RECIST v1.1 (iRECIST).

Time frame:
Baseline up to 2 years and approximately 5 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) According to iRECIST
Percentage of ParticipantsAtezolizumab Plus Bevacizumab
Disease Control Rate (DCR) According to iRECIST65.2 (42.73 to 83.62)
SecondaryDuration of Objective Response (DOR) According to iRECIST

Duration of objective response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Median · Months
Duration of Objective Response (DOR) According to iRECIST
MonthsAtezolizumab Plus Bevacizumab
Duration of Objective Response (DOR) According to iRECIST6.36 (2.66 to NA)
SecondaryProgression-Free Survival (PFS) According to iRECIST

Progression-free survival (PFS) is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).

Time frame:
Baseline up to approximately 2.5 years
Reported as:
Median · Months
Progression-Free Survival (PFS) According to iRECIST
MonthsAtezolizumab Plus Bevacizumab
Progression-Free Survival (PFS) According to iRECIST2.76 (1.35 to 4.07)
SecondaryProgression-Free Survival (PFS) Rate at 12 Months According to iRECIST

Progression-free survival (PFS) rate is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first at 12 months, as determined by the investigator according to modified RECIST v1.1 (iRECIST).

Time frame:
Baseline up to approximately 12 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST
MonthsAtezolizumab Plus Bevacizumab
Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST4.64 (0.33 to 19.26)
SecondaryTime to Deterioation (TTD) Using EORTC

Time to deterioration (TTD) using European Organization for Research and treatment of Cancer (EORTC) Quality-of-life Questionnaire Core 30 (QLQ C30) and its Lung Cancer Module (QLQ LC13) is defined as the time from baseline to the first time the patient's score shows a \>=10 points increase above baseline in any of the following EORTC-transformed symptom subscale scores (whichever occurs first): cough, dyspnoea (single item), dyspnoea (multi-item subscale), chest pain, or arm/shoulder pain, whichever occurred first. Scores ranged from 0-10. A higher score represented more severe symptoms.

Time frame:
Baselsine up to approximately 1 year
Reported as:
Median · Months
Time to Deterioation (TTD) Using EORTC
MonthsAtezolizumab Plus Bevacizumab
CoughNA (3.48 to NA)
Dyspnoea (single-item Q33)NA (NA to NA)
Dyspnoea (single-item Q34)NA (NA to NA)
Dyspnoea (single-item Q35)NA (NA to NA)
Dyspnoea (multi-item)NA (NA to NA)
Chest painNA (2.10 to NA)
Arm/shoulder painNA (NA to NA)
SecondaryChange From Baseline in Health-Related Quality of Life (HRQoL) and Health Status

The 30-item EORTC QLQ-C30 version 3 is composed by five multi-item function scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), six single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), and a two-item global quality of life scale. All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for the functional and general health areas represent better functional status and quality of life. Higher scores for the symptom scales represent more symptoms or problems (poor quality of life). A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.

Time frame:
Baseline up to approximately 1 year
Reported as:
Mean · Units on a scale
Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status
Units on a scaleAtezolizumab Plus Bevacizumab
Global Quality of Life (QoL) - Baseline53.409 ± 28.132
Global QoL - Treatment Cycle 020.833 ± 28.855
Global QoL - Treatment Cycle 03-0.521 ± 27.465
Global QoL - Treatment Cycle 04-6.250 ± 28.007
Global QoL - Treatment Cycle 05-15.625 ± 24.975
Global QoL - Treatment Cycle 06-16.667 ± 23.987
Global QoL - Treatment Cycle 07-23.611 ± 20.012
Global QoL - Treatment Cycle 08-20.833 ± 43.381
Global QoL - Treatment Cycle 09-36.111 ± 4.811
Global QoL - Treatment Cycle 10-22.222 ± 19.245
Global QoL - Treatment Cycle 11-30.556 ± 4.811
Global QoL - Treatment Cycle 12-27.778 ± 9.623
Global QoL - Treatment Cycle 13-33.333 ± NA
Global QoL - Treatment Cycle 14-25.000 ± 11.785
Global QoL - Treatment Cycle 15-33.333 ± 0.000
Global QoL - Follow Up-16.667 ± NA
Global QoL - Follow Up 2-16.667 ± NA
Global QoL - Follow Up 3-25.000 ± NA
Physical Functioning - Baseline79.091 ± 15.437
Physical Functioning - Treatment Cycle 02-5.667 ± 20.207
Physical Functioning - Treatment Cycle 03-4.167 ± 15.490
Physical Functioning - Treatment Cycle 04-0.556 ± 11.177
Physical Functioning - Treatment Cycle 05-1.667 ± 14.584
Physical Functioning - Treatment Cycle 06-0.833 ± 10.947
Physical Functioning - Treatment Cycle 07-6.667 ± 10.328
Physical Functioning - Treatment Cycle 08-8.889 ± 10.037
Physical Functioning - Treatment Cycle 09-15.556 ± 16.777
Physical Functioning - Treatment Cycle 10-6.667 ± 6.667
Physical Functioning - Treatment Cycle 11-6.667 ± 6.667
Physical Functioning - Treatment Cycle 12-13.333 ± 17.638
Physical Functioning - Treatment Cycle 13-6.667 ± NA
Physical Functioning - Treatment Cycle 14-6.667 ± 9.428
Physical Functioning - Treatment Cycle 150.000 ± 0.000
Physical Functioning - Follow Up0.000 ± NA
Physical Functioning - Follow Up 26.667 ± NA
Physical Functioning - Follow Up 30.000 ± NA
Role Functioning - Baseline81.061 ± 22.593
Role Functioning - Treatment Cycle 02-7.500 ± 32.307
Role Functioning - Treatment Cycle 03-7.292 ± 28.525
Role Functioning - Treatment Cycle 04-4.167 ± 14.434
Role Functioning - Treatment Cycle 05-4.167 ± 21.362
Role Functioning - Treatment Cycle 06-4.167 ± 14.773
Role Functioning - Treatment Cycle 070.000 ± 21.082
Role Functioning - Treatment Cycle 08-8.333 ± 25.276
Role Functioning - Treatment Cycle 09-11.111 ± 19.245
Role Functioning - Treatment Cycle 10-11.111 ± 9.623
Role Functioning - Treatment Cycle 110 ± 0
Role Functioning - Treatment Cycle 12-5.556 ± 9.623
Role Functioning - Treatment Cycle 130.000 ± NA
Role Functioning - Treatment Cycle 140.000 ± 0.000
Role Functioning - Treatment Cycle 150.000 ± 0.000
Role Functioning - Follow Up0.000 ± NA
Role Functioning - Follow Up 20.000 ± NA
Role Functioning - Follow Up 30.000 ± NA
Emotional Functioning - Baseline76.894 ± 23.561
Emotional Functioning - Treatment Cycle 02-2.083 ± 18.312
Emotional Functioning - Treatment Cycle 03-0.521 ± 20.965
Emotional Functioning - Treatment Cycle 040.000 ± 28.868
Emotional Functioning - Treatment Cycle 05-5.208 ± 23.544
Emotional Functioning - Treatment Cycle 06-4.167 ± 19.920
Emotional Functioning - Treatment Cycle 07-12.500 ± 22.822
Emotional Functioning - Treatment Cycle 08-8.333 ± 15.811
Emotional Functioning - Treatment Cycle 09-13.889 ± 17.347
Emotional Functioning - Treatment Cycle 10-16.667 ± 14.434
Emotional Functioning - Treatment Cycle 11-19.444 ± 26.788
Emotional Functioning - Treatment Cycle 12-2.778 ± 12.729
Emotional Functioning - Treatment Cycle 130.000 ± NA
Emotional Functioning - Treatment Cycle 144.167 ± 5.893
Emotional Functioning - Treatment Cycle 154.167 ± 5.893
Emotional Functioning - Follow Up0.000 ± NA
Emotional Functioning - Follow Up 20.000 ± NA
Emotional Functioning - Follow Up 30.000 ± NA
Cognitive Functioning - Baseline79.545 ± 17.006
Cognitive Functioning - Treatment Cycle 021.667 ± 17.014
Cognitive Functioning - Treatment Cycle 03-2.083 ± 14.751
Cognitive Functioning - Treatment Cycle 041.389 ± 15.006
Cognitive Functioning - Treatment Cycle 05-8.333 ± 17.817
Cognitive Functioning - Treatment Cycle 062.083 ± 13.909
Cognitive Functioning - Treatment Cycle 07-16.667 ± 25.820
Cognitive Functioning - Treatment Cycle 08-11.111 ± 17.213
Cognitive Functioning - Treatment Cycle 09-5.556 ± 9.623
Cognitive Functioning - Treatment Cycle 105.556 ± 9.623
Cognitive Functioning - Treatment Cycle 110.000 ± 0.000
Cognitive Functioning - Treatment Cycle 12-5.556 ± 9.623
Cognitive Functioning - Treatment Cycle 130.000 ± NA
Cognitive Functioning - Treatment Cycle 140.000 ± 0.000
Cognitive Functioning - Treatment Cycle 15-8.333 ± 11.785
Cognitive Functioning - Follow Up0.000 ± NA
Cognitive Functioning - Follow Up 20.000 ± NA
Cognitive Functioning - Follow Up 30.000 ± NA
Social Functioning - Baseline67.424 ± 28.857
Social Functioning - Treatment Cycle 02-3.333 ± 30.874
Social Functioning - Treatment Cycle 031.042 ± 25.436
Social Functioning - Treatment Cycle 04-1.389 ± 28.831
Social Functioning - Treatment Cycle 050.000 ± 34.503
Social Functioning - Treatment Cycle 062.083 ± 32.657
Social Functioning - Treatment Cycle 07-13.889 ± 24.553
Social Functioning - Treatment Cycle 08-11.111 ± 25.092
Social Functioning - Treatment Cycle 09-11.111 ± 25.459
Social Functioning - Treatment Cycle 10-11.111 ± 9.623
Social Functioning - Treatment Cycle 11-11.111 ± 9.623
Social Functioning - Treatment Cycle 12-5.556 ± 19.245
Social Functioning - Treatment Cycle 1316.667 ± NA
Social Functioning - Treatment Cycle 14-8.333 ± 35.355
Social Functioning - Treatment Cycle 15-8.333 ± 35.355
Social Functioning - Follow Up0.000 ± NA
Social Functioning - Follow Up 20.000 ± NA
Social Functioning - Follow Up 3-33.333 ± NA
Fatigue - Baseline34.343 ± 22.979
Fatigue - Treatment Cycle 023.889 ± 25.814
Fatigue - Treatment Cycle 038.333 ± 20.488
Fatigue - Treatment Cycle 045.556 ± 24.845
Fatigue - Treatment Cycle 058.333 ± 17.568
Fatigue - Treatment Cycle 069.722 ± 13.849
Fatigue - Treatment Cycle 079.259 ± 12.989
Fatigue - Treatment Cycle 0816.667 ± 18.257
Fatigue - Treatment Cycle 0914.815 ± 16.973
Fatigue - Treatment Cycle 1014.815 ± 16.973
Fatigue - Treatment Cycle 1118.519 ± 32.075
Fatigue - Treatment Cycle 127.407 ± 23.130
Fatigue - Treatment Cycle 130.000 ± NA
Fatigue - Treatment Cycle 140.000 ± 0.000
Fatigue - Treatment Cycle 155.556 ± 7.857
Fatigue - Follow Up0.000 ± NA
Fatigue - Follow Up 2-33.333 ± NA
Fatigue - Follow Up 3-33.333 ± NA
Nausea and Vomiting - Baseline6.818 ± 15.985
Nausea and Vomiting - Treatment Cycle 022.500 ± 9.786
Nausea and Vomiting - Treatment Cycle 033.125 ± 12.500
Nausea and Vomiting - Treatment Cycle 040.000 ± 7.107
Nausea and Vomiting - Treatment Cycle 052.083 ± 5.893
Nausea and Vomiting - Treatment Cycle 060.000 ± 0.000
Nausea and Vomiting - Treatment Cycle 070.000 ± 0.000
Nausea and Vomiting - Treatment Cycle 082.778 ± 6.804
Nausea and Vomiting - Treatment Cycle 090.000 ± 0.000
Nausea and Vomiting - Treatment Cycle 100.000 ± 0.000
Nausea and Vomiting - Treatment Cycle 110.000 ± 0.000
Nausea and Vomiting - Treatment Cycle 120.000 ± 0.000
Nausea and Vomiting - Treatment Cycle 130.000 ± NA
Nausea and Vomiting - Treatment Cycle 140.000 ± 0.000
Nausea and Vomiting - Treatment Cycle 150.000 ± 0.000
Nausea and Vomiting - Follow Up0.000 ± NA
Nausea and Vomiting - Follow Up 20.000 ± NA
Nausea and Vomiting - Follow Up 30.000 ± NA
Pain - Baseline31.061 ± 24.286
Pain -Treatment Cycle 02-2.500 ± 23.116
Pain -Treatment Cycle 03-4.167 ± 21.517
Pain -Treatment Cycle 04-1.389 ± 18.060
Pain -Treatment Cycle 056.250 ± 23.465
Pain -Treatment Cycle 064.167 ± 24.801
Pain -Treatment Cycle 075.556 ± 17.213
Pain -Treatment Cycle 0816.667 ± 29.814
Pain -Treatment Cycle 0927.778 ± 34.694
Pain -Treatment Cycle 105.556 ± 9.623
Pain -Treatment Cycle 1122.222 ± 19.245
Pain -Treatment Cycle 1211.111 ± 19.245
Pain -Treatment Cycle 130.000 ± NA
Pain -Treatment Cycle 148.333 ± 11.785
Pain -Treatment Cycle 1516.667 ± 23.570
Pain - Follow Up0.000 ± NA
Pain - Follow Up 2-16.667 ± NA
Pain - Follow Up 3-16.667 ± NA
Dyspnoea - Baseline25.758 ± 22.845
Dyspnoea - Treatment Cycle 023.333 ± 30.397
Dyspnoea - Treatment Cycle 036.250 ± 21.837
Dyspnoea - Treatment Cycle 042.778 ± 17.164
Dyspnoea - Treatment Cycle 058.333 ± 15.430
Dyspnoea - Treatment Cycle 0612.500 ± 17.252
Dyspnoea - Treatment Cycle 075.556 ± 13.608
Dyspnoea - Treatment Cycle 0811.111 ± 17.213
Dyspnoea - Treatment Cycle 0933.333 ± 0.000
Dyspnoea - Treatment Cycle 1011.111 ± 19.245
Dyspnoea - Treatment Cycle 1111.111 ± 19.245
Dyspnoea - Treatment Cycle 1211.111 ± 19.245
Dyspnoea - Treatment Cycle 1333.333 ± NA
Dyspnoea - Treatment Cycle 1416.667 ± 23.570
Dyspnoea - Treatment Cycle 1516.667 ± 23.570
Dyspnoea - Follow Up0.000 ± NA
Dyspnoea - Follow Up 20.000 ± NA
Dyspnoea - Follow Up 3-33.333 ± NA
Insomnia - Baseline27.273 ± 22.150
Insomnia - Treatment Cycle 025.000 ± 29.170
Insomnia - Treatment Cycle 036.250 ± 27.806
Insomnia - Treatment Cycle 040.000 ± 24.618
Insomnia - Treatment Cycle 054.167 ± 27.817
Insomnia - Treatment Cycle 068.333 ± 29.547
Insomnia - Treatment Cycle 075.556 ± 25.092
Insomnia - Treatment Cycle 080.000 ± 29.814
Insomnia - Treatment Cycle 0911.111 ± 19.245
Insomnia - Treatment Cycle 1011.111 ± 19.245
Insomnia - Treatment Cycle 1122.222 ± 19.245
Insomnia - Treatment Cycle 1211.111 ± 19.245
Insomnia - Treatment Cycle 130.000 ± NA
Insomnia - Treatment Cycle 140.000 ± 0.000
Insomnia - Treatment Cycle 1516.667 ± 23.570
Insomnia - Follow Up0.000 ± NA
Insomnia - Follow Up 20.000 ± NA
Insomnia - Follow Up 30.000 ± NA
Appetite Loss - Baseline27.273 ± 24.422
Appetite Loss - Treatment Cycle 02-1.667 ± 29.568
Appetite Loss - Treatment Cycle 03-6.250 ± 27.806
Appetite Loss - Treatment Cycle 042.778 ± 22.285
Appetite Loss - Treatment Cycle 054.167 ± 21.362
Appetite Loss - Treatment Cycle 064.167 ± 21.362
Appetite Loss - Treatment Cycle 07-5.556 ± 13.608
Appetite Loss - Treatment Cycle 080.000 ± 21.082
Appetite Loss - Treatment Cycle 09-11.111 ± 19.245
Appetite Loss - Treatment Cycle 100.000 ± 33.333
Appetite Loss - Treatment Cycle 1111.111 ± 19.245
Appetite Loss - Treatment Cycle 12-11.111 ± 19.245
Appetite Loss - Treatment Cycle 130.000 ± NA
Appetite Loss - Treatment Cycle 1416.667 ± 23.570
Appetite Loss - Treatment Cycle 1516.667 ± 23.570
Appetite Loss - Follow Up33.333 ± NA
Appetite Loss - Follow Up 20.000 ± NA
Appetite Loss - Follow Up 30.000 ± NA
Constipation - Baseline15.152 ± 16.988
Constipation - Treatment Cycle 02-3.333 ± 23.939
Constipation - Treatment Cycle 036.250 ± 30.353
Constipation - Treatment Cycle 04-5.556 ± 12.975
Constipation - Treatment Cycle 05-4.167 ± 21.362
Constipation - Treatment Cycle 06-8.333 ± 15.430
Constipation - Treatment Cycle 07-5.556 ± 13.608
Constipation - Treatment Cycle 08-5.556 ± 13.608
Constipation - Treatment Cycle 09-11.111 ± 19.245
Constipation - Treatment Cycle 100.000 ± 33.333
Constipation - Treatment Cycle 1111.111 ± 19.245
Constipation - Treatment Cycle 120.000 ± 33.333
Constipation - Treatment Cycle 1333.333 ± NA
Constipation - Treatment Cycle 140.000 ± 0.000
Constipation - Treatment Cycle 1516.667 ± 23.570
Constipation - Follow Up0.000 ± NA
Constipation - Follow Up 20.000 ± NA
Constipation - Follow Up 30.000 ± NA
Diarrhoea - Baseline9.091 ± 18.349
Diarrhoea - Treatment Cycle 02-3.333 ± 18.417
Diarrhoea - Treatment Cycle 03-4.167 ± 20.638
Diarrhoea - Treatment Cycle 04-8.333 ± 20.719
Diarrhoea - Treatment Cycle 05-4.167 ± 11.785
Diarrhoea - Treatment Cycle 06-4.167 ± 11.785
Diarrhoea - Treatment Cycle 07-5.556 ± 13.608
Diarrhoea - Treatment Cycle 080.000 ± 21.082
Diarrhoea - Treatment Cycle 09-11.111 ± 19.245
Diarrhoea - Treatment Cycle 10-11.111 ± 19.245
Diarrhoea - Treatment Cycle 110.000 ± 33.333
Diarrhoea - Treatment Cycle 12-11.111 ± 19.245
Diarrhoea - Treatment Cycle 130.000 ± NA
Diarrhoea - Treatment Cycle 140.000 ± 0.000
Diarrhoea - Treatment Cycle 1516.667 ± 23.570
Diarrhoea - Follow Up0.000 ± NA
Diarrhoea - Follow Up 20.000 ± NA
Diarrhoea - Follow Up 30.000 ± NA
Financial Difficulties - Baseline60.606 ± 33.549
Financial Difficulties - Treatment Cycle 02-8.333 ± 26.213
Financial Difficulties - Treatment Cycle 03-10.417 ± 26.440
Financial Difficulties - Treatment Cycle 04-11.111 ± 25.950
Financial Difficulties - Treatment Cycle 05-16.667 ± 25.198
Financial Difficulties - Treatment Cycle 06-33.333 ± 30.861
Financial Difficulties - Treatment Cycle 07-27.778 ± 32.773
Financial Difficulties - Treatment Cycle 08-22.222 ± 40.369
Financial Difficulties - Treatment Cycle 09-22.222 ± 50.918
Financial Difficulties - Treatment Cycle 10-22.222 ± 50.918
Financial Difficulties - Treatment Cycle 11-11.111 ± 50.918
Financial Difficulties - Treatment Cycle 12-11.111 ± 50.918
Financial Difficulties - Treatment Cycle 13-66.667 ± NA
Financial Difficulties - Treatment Cycle 140.000 ± 0.000
Financial Difficulties - Treatment Cycle 15-16.667 ± 23.570
Financial Difficulties - Follow Up0.000 ± NA
Financial Difficulties - Follow Up 2-33.333 ± NA
Financial Difficulties - Follow Up 3-33.333 ± NA
SecondaryChange From Baseline in Lung Cancer Related Symptoms

The EORTC QLQ-LC13 is a specific module for lung cancer. It consists of 13 items covering lung cancer symptoms (dyspnoea, coughing, hemoptysis, pain in chest, pain in arm or shoulder and pain in other parts) and the side effects of chemo- and radiotherapy (alopecia, peripheral neuropathy, sore mouth, and dysphagia), which are divided into 10 fields, all are symptom types. All EORTC symptom scores are linearly transformed so that each score has a range of 0-100. A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.

Time frame:
Baseline up to approximately 1 year
Reported as:
Mean · Units on a scale
Change From Baseline in Lung Cancer Related Symptoms
Units on a scaleAtezolizumab Plus Bevacizumab
Dyspnoea - Baseline34.343 ± 20.260
Dyspnoea - Treatment Cycle 02-5.556 ± 18.557
Dyspnoea - Treatment Cycle 03-2.778 ± 20.488
Dyspnoea - Treatment Cycle 04-4.630 ± 16.723
Dyspnoea - Treatment Cycle 05-2.778 ± 19.473
Dyspnoea - Treatment Cycle 065.556 ± 16.798
Dyspnoea - Treatment Cycle 070.000 ± 14.055
Dyspnoea - Treatment Cycle 080.000 ± 22.222
Dyspnoea - Treatment Cycle 0911.111 ± 0.000
Dyspnoea - Treatment Cycle 107.407 ± 16.973
Dyspnoea - Treatment Cycle 117.407 ± 6.415
Dyspnoea - Treatment Cycle 127.407 ± 16.973
Dyspnoea - Treatment Cycle 1311.111 ± NA
Dyspnoea - Follow Up-22.222 ± NA
Dyspnoea - Follow Up 2-22.222 ± NA
Dyspnoea - Follow Up 3-33.333 ± NA
Coughing - Baseline37.879 ± 31.363
Coughing - Treatment Cycle 021.667 ± 25.305
Coughing - Treatment Cycle 0310.417 ± 23.472
Coughing - Treatment Cycle 040.000 ± 14.213
Coughing - Treatment Cycle 054.167 ± 21.362
Coughing - Treatment Cycle 0616.667 ± 30.861
Coughing - Treatment Cycle 070.000 ± 21.082
Coughing - Treatment Cycle 0811.111 ± 34.427
Coughing - Treatment Cycle 090.000 ± 0.000
Coughing - Treatment Cycle 10-11.111 ± 19.245
Coughing - Treatment Cycle 11-11.111 ± 19.245
Coughing - Treatment Cycle 12-11.111 ± 19.245
Coughing - Treatment Cycle 130.000 ± NA
Coughing - Treatment Cycle 140.000 ± 47.140
Coughing - Treatment Cycle 150.000 ± 0.00
Coughing - Follow Up-33.333 ± NA
Coughing - Follow Up 2-33.333 ± NA
Coughing - Follow Up 3-66.667 ± NA
Hemoptysis - Baseline4.545 ± 15.585
Hemoptysis - Treatment Cycle 02-1.667 ± 13.134
Hemoptysis - Treatment Cycle 03-2.083 ± 8.333
Hemoptysis - Treatment Cycle 040.000 ± 0.000
Hemoptysis - Treatment Cycle 05-4.167 ± 11.785
Hemoptysis - Treatment Cycle 060.000 ± 0.000
Hemoptysis - Treatment Cycle 070.000 ± 0.000
Hemoptysis - Treatment Cycle 0811.111 ± 27.217
Hemoptysis - Treatment Cycle 090.000 ± 0.000
Hemoptysis - Treatment Cycle 100.000 ± 0.000
Hemoptysis - Treatment Cycle 110.000 ± 0.000
Hemoptysis - Treatment Cycle 120.000 ± 0.000
Hemoptysis - Treatment Cycle 130.000 ± NA
Hemoptysis - Treatment Cycle 140.000 ± 0.000
Hemoptysis - Treatment Cycle 150.000 ± 0.000
Hemoptysis - Follow Up0.000 ± NA
Hemoptysis - Follow Up 20.000 ± NA
Hemoptysis - Follow Up 30.000 ± NA
Sore mouth - Baseline3.030 ± 9.808
Sore mouth - Treatment Cycle 026.667 ± 20.520
Sore mouth - Treatment Cycle 034.167 ± 20.638
Sore mouth - Treatment Cycle 040.000 ± 20.101
Sore mouth - Treatment Cycle 054.167 ± 11.785
Sore mouth - Treatment Cycle 06-4.167 ± 11.785
Sore mouth - Treatment Cycle 075.556 ± 13.608
Sore mouth - Treatment Cycle 085.556 ± 13.608
Sore mouth - Treatment Cycle 090.000 ± 0.000
Sore mouth - Treatment Cycle 100.000 ± 0.000
Sore mouth - Treatment Cycle 110.000 ± 0.000
Sore mouth - Treatment Cycle 120.000 ± 0.000
Sore mouth - Treatment Cycle 130.000 ± NA
Sore mouth - Treatment Cycle 140.000 ± 0.000
Sore mouth - Treatment Cycle 150.000 ± 0.000
Sore mouth - Follow Up0.000 ± NA
Sore mouth - Follow Up 20.000 ± NA
Sore mouth - Follow Up 30.000 ± NA
Dysphagia - Baseline10.606 ± 15.891
Dysphagia - Treatment Cycle 025.000 ± 24.839
Dysphagia - Treatment Cycle 030.000 ± 12.172
Dysphagia - Treatment Cycle 04-2.778 ± 9.623
Dysphagia - Treatment Cycle 050.000 ± 0.000
Dysphagia - Treatment Cycle 06-8.333 ± 15.430
Dysphagia - Treatment Cycle 07-5.556 ± 13.608
Dysphagia - Treatment Cycle 08-5.556 ± 13.608
Dysphagia - Treatment Cycle 09-11.111 ± 19.245
Dysphagia - Treatment Cycle 10-11.111 ± 19.245
Dysphagia - Treatment Cycle 11-11.111 ± 19.245
Dysphagia - Treatment Cycle 12-11.111 ± 19.245
Dysphagia - Treatment Cycle 130.000 ± NA
Dysphagia - Treatment Cycle 14-16.667 ± 23.570
Dysphagia - Treatment Cycle 15-16.667 ± 23.570
Dysphagia - Follow Up-33.333 ± NA
Dysphagia - Follow Up 2-33.333 ± NA
Dysphagia - Follow Up 3-33.333 ± NA
Peripheral neuropathy - Baseline9.091 ± 18.349
Peripheral neuropathy - Treatment Cycle 026.5667 ± 23.195
Peripheral neuropathy - Treatment Cycle 034.167 ± 16.667
Peripheral neuropathy - Treatment Cycle 048.333 ± 15.076
Peripheral neuropathy - Treatment Cycle 0512.500 ± 17.252
Peripheral neuropathy - Treatment Cycle 0612.500 ± 17.252
Peripheral neuropathy - Treatment Cycle 0711.111 ± 17.213
Peripheral neuropathy - Treatment Cycle 0811.111 ± 17.213
Peripheral neuropathy - Treatment Cycle 090.000 ± 0.000
Peripheral neuropathy - Treatment Cycle 100.000 ± 0.000
Peripheral neuropathy - Treatment Cycle 1111.111 ± 19.245
Peripheral neuropathy - Treatment Cycle 120.000 ± 0.000
Peripheral neuropathy - Treatment Cycle 130.000 ± NA
Peripheral neuropathy - Treatment Cycle 140.000 ± 0.000
Peripheral neuropathy - Treatment Cycle 150.000 ± 0.000
Peripheral neuropathy - Follow Up0.000 ± NA
Peripheral neuropathy - Follow Up 20.000 ± NA
Peripheral neuropathy - Follow Up 30.000 ± NA
Alopecia -Baseline16.667 ± 26.726
Alopecia - Treatment Cycle 02-3.333 ± 18.417
Alopecia - Treatment Cycle 03-12.500 ± 29.502
Alopecia - Treatment Cycle 04-13.889 ± 22.285
Alopecia - Treatment Cycle 05-8.333 ± 23.570
Alopecia - Treatment Cycle 06-12.500 ± 24.801
Alopecia - Treatment Cycle 07-5.556 ± 25.092
Alopecia - Treatment Cycle 08-5.556 ± 25.092
Alopecia - Treatment Cycle 09-11.111 ± 19.245
Alopecia - Treatment Cycle 10-11.111 ± 19.245
Alopecia - Treatment Cycle 11-11.111 ± 19.245
Alopecia - Treatment Cycle 12-11.111 ± 19.245
Alopecia - Treatment Cycle 130.000 ± NA
Alopecia - Treatment Cycle 14-16.667 ± 23.570
Alopecia - Treatment Cycle 15-16.667 ± 23.570
Alopecia - Follow Up-33.333 ± NA
Alopecia - Follow Up 2-33.333 ± NA
Alopecia - Follow Up 3-33.333 ± NA
Pain in chest - Baseline31.818 ± 29.951
Pain in chest - Treatment Cycle 021.667 ± 29.568
Pain in chest - Treatment Cycle 030.000 ± 29.814
Pain in chest - Treatment Cycle 042.778 ± 22.285
Pain in chest - Treatment Cycle 054.167 ± 33.034
Pain in chest - Treatment Cycle 060.000 ± 25.198
Pain in chest - Treatment Cycle 075.556 ± 32.773
Pain in chest - Treatment Cycle 08-5.556 ± 25.092
Pain in chest - Treatment Cycle 09-11.111 ± 19.245
Pain in chest - Treatment Cycle 10-11.111 ± 19.245
Pain in chest - Treatment Cycle 11-11.111 ± 19.245
Pain in chest - Treatment Cycle 12-11.111 ± 19.245
Pain in chest - Treatment Cycle 130.000 ± NA
Pain in chest - Treatment Cycle 14-16.667 ± 23.570
Pain in chest - Treatment Cycle 15-16.667 ± 23.570
Pain in chest - Follow Up-33.333 ± NA
Pain in chest - Follow Up 2-33.333 ± NA
Pain in chest - Follow Up 3-33.333 ± NA
Pain in arm or shoulder -Baseline22 ± 27.273
Pain in arm or shoulder -Treatment Cycle 02-6.667 ± 31.715
Pain in arm or shoulder -Treatment Cycle 03-12.500 ± 36.260
Pain in arm or shoulder -Treatment Cycle 04-8.333 ± 35.176
Pain in arm or shoulder -Treatment Cycle 05-4.167 ± 45.207
Pain in arm or shoulder -Treatment Cycle 06-4.167 ± 41.547
Pain in arm or shoulder -Treatment Cycle 075.556 ± 25.092
Pain in arm or shoulder -Treatment Cycle 0822.222 ± 40.369
Pain in arm or shoulder -Treatment Cycle 0933.333 ± 57.735
Pain in arm or shoulder -Treatment Cycle 1011.111 ± 50.918
Pain in arm or shoulder -Treatment Cycle 1111.111 ± 50.918
Pain in arm or shoulder -Treatment Cycle 1211.111 ± 50.918
Pain in arm or shoulder -Treatment Cycle 130.000 ± NA
Pain in arm or shoulder -Treatment Cycle 1450.000 ± 70.711
Pain in arm or shoulder -Treatment Cycle 1516.667 ± 23.570
Pain in arm or shoulder - Follow Up33.333 ± NA
Pain in arm or shoulder - Follow Up 20.000 ± NA
Pain in arm or shoulder - Follow Up 333.333 ± NA
Pain in other parts - Baseline25.758 ± 28.971
Pain in other parts - Treatment Cycle 02-3.333 ± 23.939
Pain in other parts - Treatment Cycle 03-2.083 ± 22.669
Pain in other parts - Treatment Cycle 042.778 ± 22.285
Pain in other parts - Treatment Cycle 0516.667 ± 25.198
Pain in other parts - Treatment Cycle 06-4.167 ± 21.362
Pain in other parts - Treatment Cycle 07-5.556 ± 25.092
Pain in other parts - Treatment Cycle 085.556 ± 32.773
Pain in other parts - Treatment Cycle 09-11.111 ± 19.245
Pain in other parts - Treatment Cycle 10-11.111 ± 19.245
Pain in other parts - Treatment Cycle 11-11.111 ± 19.245
Pain in other parts - Treatment Cycle 12-11.111 ± 19.245
Pain in other parts - Treatment Cycle 130.000 ± NA
Pain in other parts - Treatment Cycle 14-16.667 ± 23.570
Pain in other parts - Treatment Cycle 15-16.667 ± 23.570
Pain in other parts - Follow Up-33.333 ± NA
Pain in other parts - Follow Up 2-33.333 ± NA
Pain in other parts - Follow Up 3-33.333 ± NA

Adverse events

Collected over Baseline up to approximately 2.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atezolizumab Plus Bevacizumab17/23 (73.9%)4/23 (17.4%)23/23 (100%)
Most frequent serious events
Most frequent serious events
EventAtezolizumab Plus Bevacizumab
DeathGeneral disorders1/23
MalaiseGeneral disorders1/23
Left ventricular dysfunctionCardiac disorders1/23
GastroenteritisInfections and infestations1/23
PneumoniaInfections and infestations1/23
Upper respiratory tract infectionInfections and infestations1/23
Platelet count decreasedInvestigations1/23
Most frequent other events
Showing 10 of 34
Most frequent other events
EventAtezolizumab Plus Bevacizumab
ProteinuriaRenal and urinary disorders7/23
FatigueGeneral disorders6/23
Aspartate aminotransferase increasedInvestigations6/23
HypertensionVascular disorders6/23
AnaemiaBlood and lymphatic system disorders5/23
Urinary tract infectionInfections and infestations5/23
Blood thyroid stimulating hormone increasedInvestigations5/23
Platelet count decreasedInvestigations5/23
Decreased appetiteMetabolism and nutrition disorders5/23
HypercholesterolaemiaMetabolism and nutrition disorders5/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Atezolizumab Plus Bevacizumab
Mean59.8 ± 10.07
Sex: Female, Male
Sex: Female, Male(Participants)Atezolizumab Plus Bevacizumab
Female13
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atezolizumab Plus Bevacizumab
American Indian or Alaska Native0
Asian23
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Smoking History
Smoking History(Participants)Atezolizumab Plus Bevacizumab
Never16
Current0
Previous7
08

Study locations

10 sites
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Beijing Hospital; Internal Medicine-Oncology
    Beijing, 100730, China
  • Beijing Chest Hospital; Oncology Department
    Beijing, 101149, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Sun Yet-sen University Cancer Center
    Guangzhou City, 510663, China
  • Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department
    Hangzhou City, 310022, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Shandong Cancer Hospital
    Jinan, 250117, China
  • Guangxi Cancer Hospital of Guangxi Medical University
    Nanning City, 530021, China
  • The Affiliated Hospital of Medical College Qingdao University
    Qingdao, 266000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2022, 16 months.

Results were first posted in Apr 2023, 1 year 2 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 16 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Jun 11, 2020
StartActual
Sep 9, 2020
Primary completionActual
Jan 19, 2022
CompletionActual
Feb 10, 2023
Results first posted
Apr 13, 2023
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04426825
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Sep 9, 2020
Primary completion
Jan 19, 2022
Completion
Feb 10, 2023
Results posted
Apr 13, 2023
Last update
May 21, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion